A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are
described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and
recent evidence suggested a detrimental effect on asthma control as well as an increased …

Background When first developed more than 30 years ago, beta-agonists (eg, isoproterenol)
did not discriminate between beta 1-and beta 2-subtypes of the beta-adrenoceptor, resulting …

The addition of an inhaled long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS)
gives optimal control of asthma in most patients and two fixed combination inhalers …

The introduction of long-acting b-agonist (LABA) drugs in the 1990s was considered a major
advance in bronchodilator therapy with evidence that their use led to improved lung function …

Twice-daily combination therapy of inhaled corticosteroids and long-acting β 2-adrenoceptor
agonists (LABA) is now established as a most effective treatment for moderate to severe …

Formoterol and salmeterol are both long-acting bronchodilators that are effective in the
treatment of asthma. However, some differences exist in their pharmacology that are …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

There is unequivocal evidence that the combination of an inhaled corticosteroid (ICS)—ie
glucocorticoid—and an inhaled long‐acting β2‐adrenoceptor agonist (LABA) is superior to …